STIM at a glance
Neuronetics, Inc. (STIM, SEC CIK 1227636) filed its latest 10-K annual report on March 17, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on August 17, 2026 and Form 4 insider filings as recently as August 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Neuronetics, Inc. (STIM) reported revenue of $149.2 million (up 99.2% from FY2024) and a net loss of $39.0 million. Diluted EPS was -$0.59.
- As of June 30, 2026, 18 institutional investment managers tracked by SignalX reported holding Neuronetics, Inc. (STIM) shares worth $4.9 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Chernett Jorey on August 14, 2026 of 14,000 shares at $3.16 per share.
- In the last 90 days, STIM insiders reported 2 open-market purchases ($107K) and 0 open-market sales ($0) on Form 4, a net purchase of $107K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $149.2M
- +99.2% vs prior year
- Insiders · 90 days
- 2 buys · 0 sells
- Net +$107K
- 13F holders
- 18 funds
- $4.9M · −1 vs prior quarter
- Latest 8-K
- Aug 17, 2026
- Item 5.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: Development and commercialization of NeuroStar Advanced Therapy System, a non-invasive TMS treatment for MDD and OCD, plus operation of Greenbrook mental health treatment centers
- New emphasis on fully integrated care via Greenbrook acquisition, adding 93 clinics and SPRAVATO treatment for treatment-resistant depression
- Strategic shift to vertically integrated provider of mental health solutions combining product and service, aiming for market consolidation and expanded patient access
- Revenue $149.2M in 2025, up 99% YoY; increased U.S. clinic revenues to 59% from 6% prior year due to Greenbrook acquisition; 658 employees as of December 2025
- Noteworthy Greenbrook restructuring closing dozens of underperforming clinics and focus on Regional Account Managers to build referral pathways
Risk Factors
- Cybersecurity risk oversight by board Audit Committee with quarterly enterprise risk profile reports from Head of IT
- Head of IT with 20+ years experience leads cybersecurity program and partners with third-party experts for risk identification
- Regular assessment using industry-standard KPIs for prevention, detection, mitigation, and remediation of cybersecurity incidents
Management Discussion & Analysis
- Revenue $149.2M in 2025, up 99% YoY from $74.9M in 2024; U.S. revenue $146.0M up 101% YoY; international $3.1M up 29% YoY
- Gross margin 48.5% in 2025 vs 72.3% in 2024, decline due to Greenbrook clinic business inclusion and reduced treatment session revenue
- Best performing segment: Clinic revenue $87.0M (59% of US revenues) in 2025 vs $4.4M (6%) in 2024; Worst: NeuroStar System revenue $14.3M (10%) in 2025 vs $15.3M (21%) in 2024
- Operating loss improved to $(31.4)M from $(34.6)M; net loss $(39.1)M vs $(43.7)M; cash $28.1M with operating cash flow negative $20.4M; $70M debt outstanding; raised $26.8M net via equity offerings and ATM
- Management expects clinic revenue growth in 2026; anticipates decreased sales/marketing expense but increased general/administrative expense; key risks include financing availability and regulatory challenges
AI summary of the STIM 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Quarterly revenue $41.6M, up $3.5M or 9% YoY from $38.1M
- Greenbrook strongest segment, 65% of quarterly revenue versus NeuroStar at 35%
- Net loss $3.5M versus $9.8M YoY
- Six-month net loss $14.2M versus $22.5M YoY
- Management expects clinic revenue to increase in 2026; macroeconomic pressures remain headwinds
Risk Factors
- No material changes identified; filing refers readers to 10-K filed March 17, 2026 and 10-Q filed May 5, 2026
- Credit risk carried forward through Credit Agreement and Guaranty with Perceptive Credit Holdings IV, LP
- Financing risk heightened by Credit Agreement Amendment No. 5 and Waiver dated March 12, 2026
- Management continuity risk following executive separation agreement dated July 17, 2026
- Compensation and retention risk following adoption of 2026 Equity Incentive Plan
AI summary of the STIM 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Nir Naor now serves as principal financial and accounting officer, consolidating CFO and accounting oversight
- Francis X. Brown III ended interim finance leadership on August 11, 2026 and remains a consultant
Item 2.02: Results of Operations and Financial Condition
- Q2 and first-half 2026 financial results announced for periods ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing the substantive results investors should review
Item 7.01: Regulation FD Disclosure
- Reg FD disclosure frames fiscal 2026 outlook for revenue, expenses, growth, and upcoming quarters as forward-looking
- Greenbrook TMS transaction identified as a key uncertainty affecting business relationships and operating results
Item EX-99.1: Item EX-99.1
- Q2 revenue $41.6M, up 9.1%, driven by Greenbrook revenue $26.9M, up 16.8%
- NeuroStar revenue declined 2.7% to $14.7M, highlighting continued pressure in the core device business
Item 5.02: Departure/Appointment of Directors or Principal Officers
- CFO W. Andrew Macan departs August 15, 2026, with $231,750 retention bonus, 164,361 RSUs, and $475,087.50 separation payment
- Company stated Macan’s departure reflects no dispute with management, the Board, or Company policies
Item EX-99.1: Item EX-99.1
- Nir Naor appointed CFO effective July 23, 2026, adding more than 20 years of finance and life sciences experience
- Naor receives 500,000 restricted stock units, vesting in equal installments over four years
Item 7.01: Regulation FD Disclosure
- CFO and Treasurer Naor appointed, establishing new finance leadership
- Cory Anderson promoted to Executive Vice President and General Manager of Greenbrook
AI summaries of STIM 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for STIM
Don't miss the next STIM filing
- Alerts as it files. A push when STIM files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut STIM, by share count.
- Ask anything. An AI agent that reads every STIM filing and answers with sources.
STIM alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Chernett Jorey | Buy | Aug 14, 2026 | 14,000 | $3.16 |
| Chernett Jorey | Sell | Aug 13, 2026 | 100 | $3.21 |
| Naor Nir | A | Jul 23, 2026 | 500,000 | - |
| Chernett Jorey | Buy | Jul 14, 2026 | 35,000 | $1.78 |
| Amin Avinash | J | Jun 15, 2026 | 2,934 | - |
| Madryn Asset Management, LP | J | Jun 15, 2026 | 34,932 | - |
| Madryn Asset Management, LP | J | Jun 15, 2026 | 4,634 | - |
| Amin Avinash | J | Jun 15, 2026 | 4,634 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $74.9M | $149.2M |
| Gross Profit | $51.7M | $54.2M | $72.3M |
| Operating Income | - | -$34.6M | -$31.4M |
| Net Income | -$30.2M | -$43.7M | -$39.0M |
| Gross Margin | - | 72.3% | 48.5% |
| Op. Margin | - | -46.2% | -21.1% |
| Net Margin | - | -58.4% | -26.1% |
| Balance Sheet | |||
| Total Assets | - | $140.9M | $141.6M |
| Equity | $34.2M | $27.7M | $22.4M |
| ROE | -88.3% | -157.8% | -174.3% |
| Per Share | |||
| EPS | $-1.05 | $-1.38 | $-0.59 |
| Cash Flow | |||
| Operating CF | - | -$31.0M | -$20.4M |
Source: XBRL data in Neuronetics, Inc. (STIM)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate STIM share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 18 | $4.9M |
| Q1 2026 | 19 | $9.7M |
| Q4 2025 | 20 | $10.3M |
| Q3 2025 | 21 | $21.8M |
| Q2 2025 | 18 | $29.5M |
| Q1 2025 | 16 | $18.1M |
| Q4 2024 | 6 | $2.7M |
| Q3 2024 | 4 | $586,000 |
- Citadel Advisors LLC+345.3K (+451%)
- Goldman Sachs Group+30.5K (+13%)
- Morgan Stanley+22.8K (+57%)
- AQR Capital Management+1.1K (+1%)
- BlackRock−1.72M (-74%)
- State Street Corp−552.2K (-66%)
- Vanguard Capital Management LLC−540.9K (-26%)
- Northern Trust−188.2K (-68%)
- Citigroup−54.0K (-95%)
- Millennium Management+199.4K
- StoneX Group Inc.+12.1K
- Vanguard Portfolio Management LLC−221.2K
- Citizens Financial Group−111.0K
- BNY Mellon−78.6K
Source: 13F-HR filings on SEC EDGAR (aggregated from 122 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
STIM filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Aug 17, 2026 | - | - | - |
| 8-K | Aug 17, 2026 | - | Analysis | - |
| SC 13G | Aug 14, 2026 | - | - | |
| 10-Q | Aug 11, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 4 | Jul 23, 2026 | - | - | - |
| 8-K | Jul 20, 2026 | - | Analysis | - |
| 4 | Jul 15, 2026 | - | - | - |
| 8-K | Jun 23, 2026 | - | Analysis | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | May 29, 2026 | - | - | |
| 4 | May 29, 2026 | - | - | |
| 4 | May 29, 2026 | - | - | |
| 4 | May 29, 2026 | - | - | |
| 4 | May 29, 2026 | - | - | |
| 8-K | May 29, 2026 | - | Analysis | |
| 4 | May 29, 2026 | - | - | |
| 8-K | May 22, 2026 | - | Analysis | |
| 4 | May 21, 2026 | - | - | |
| 4 | May 20, 2026 | - | - | |
| 4 | May 13, 2026 | - | - | |
| 8-K | May 5, 2026 | - | Analysis | - |
| 10-Q | May 5, 2026 | Mar 31, 2026 | Analysis | |
| 4 | Apr 22, 2026 | - | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
STIM SEC filings: frequently asked questions
Are STIM insiders buying or selling?
In the last 90 days, Neuronetics, Inc. (STIM) officers, directors and 10% owners reported 2 open-market purchases worth $106,540 by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold STIM stock?
As of June 30, 2026, the largest Neuronetics, Inc. (STIM) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($2.0 million), BlackRock ($776,000), Citadel Advisors LLC ($548,000), State Street Corp ($377,000), Goldman Sachs Group ($344,000). 13F-HR reports are filed up to 45 days after each quarter ends.
What was STIM's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Neuronetics, Inc. (STIM) reported revenue of $149.2 million (up 99.2% from FY2024) and a net loss of $39.0 million. Diluted EPS was -$0.59. The figures come from the XBRL data in the 10-K.
What are the main risks in STIM's latest 10-K?
In the 10-K filed March 17, 2026, Neuronetics, Inc. (STIM) flagged: Cybersecurity risk oversight by board Audit Committee with quarterly enterprise risk profile reports from Head of IT. Head of IT with 20+ years experience leads cybersecurity program and partners with third-party experts for risk identification. (AI summary of the Risk Factors section.)
What did STIM report in its latest 8-K?
Neuronetics, Inc. (STIM) filed an 8-K on August 17, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers). Nir Naor now serves as principal financial and accounting officer, consolidating CFO and accounting oversight.
What are the latest STIM SEC filings?
Neuronetics, Inc. (STIM) filed its latest 10-K annual report on March 17, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on August 17, 2026 and a Form 4 insider filing on August 17, 2026.
What is STIM's SEC CIK number?
Neuronetics, Inc. (STIM)'s SEC Central Index Key (CIK) is 1227636. EDGAR lists every STIM filing under that number.
Ask anything about STIM
The research agent reads STIM's filings, financials, insider trades and 13F holders, then answers with sources.